In order to continue phase 3 studies with the Sinopharm vaccine in Peru, the Universidad Peruana Cayetano Heredia (UPCH) reported that they appointed Dr. Coralith García as the principal investigator of the clinical trial. The researcher is the replacement of the suspended doctor Germán Málaga, who participated in the Vacunagate scandal.
This was confirmed by the UPCH, through a statement issued this Monday, March 1. The statement also indicates that the authorities in charge as academic rector and vice-rector are Gustavo Gonzales Rengifo and Alfonso Zavaleta, respectively.
“As authorities in charge, we share the indignation and deep pain of the Heredian community and Peruvian society over the events related to the administration of the additional batch of experimental vaccines sent by Sinopharm, which has caused great damage to the image of our university. ”Says the statement.
The institution also informs that they have formed an ad hoc commission that investigates the facts and the responsibility of the researchers of this house of studies. “For this, the University Council appointed five notable former UPCH teachers and they were appointed without the participation of the resigning authorities,” he adds.
Following the disclosure of the misuse of 3,200 doses of vaccine, better known as the Vacunagate case, the National Institute of Health (INS) suspended the registration as a research center of the Center for Clinical Studies of the UPCH to carry out new studies. However, this does not affect the continuity of phase III trials of the Chinese Sinopharm vaccine.